<?xml version="1.0" encoding="UTF-8"?>
<p>The rapidly expanding SARS-CoV-2 pandemic and its threats require a quick reaction prior to the availability of (eagerly awaited) evidence on how to manage patients with chronic lymphocytic leukemia (CLL) during this pandemic. Accordingly, this document was prepared by adapting existing guidance and scientific evidence to the new scenario imposed by the SARS-CoV-2 epidemics.</p>
